GO
Loading...

FDA

More

  • U.S. District Court Judge Richard Leon ordered the FDA reconstitute the committee and barred the agency from using the panel's findings, which said removing menthol cigarettes from the market would benefit public health.

  • U.S. District Court Judge Richard Leon ordered the FDA reconstitute the committee and barred the agency from using the panel's findings, which said removing menthol cigarettes from the market would benefit public health.

  • Judge: FDA can't use tobacco panel menthol report Monday, 21 Jul 2014 | 6:25 PM ET

    U.S. District Court Judge Richard Leon in Washington ordered the FDA on Monday to reconstitute the tobacco panel and barred the agency from using its older report on menthol cigarettes.

  • NEW YORK, July 16- A proposal to overhaul nutrition labels on packaged foods sold in the United States does not go far enough to influence consumer choices and reduce obesity, a former U.S.

  • WASHINGTON, July 11- Last year the U.S. Food and Drug Administration recommended that millions of dollars in research grants be awarded to scientists serving on its tobacco advisory committee, even as it rejected several projects deemed by a National Institutes of Health panel to have greater scientific merit, according to confidential scores reviewed by Reuters.

  • July 8- Anacor Pharmaceutical Inc said the U.S. Food and Drug Administration approved its treatment for a fungal infection of the toenail. The topical solution, Kerydin, is expected to be launched as early as the end of the quarter in the United States, the company said on Tuesday.

  • In preparatory documents posted on the agency's website on Tuesday, FDA reviewers said laparoscopic power morcellator devices, which are used to treat uterine fibroids, allow for less invasive surgeries, shorter recovery time and fewer wound site infections.

  • FDA approves Anacor Pharma's drug for nail infection Tuesday, 8 Jul 2014 | 8:49 AM ET

    July 8- Anacor Pharmaceutical Inc said the U.S. Food and Drug Administration approved its treatment for a fungal infection of the nail, sending the drug developer's shares up about 9 percent in premarket trade. Onychomycosis is a progressive, recurring fungal infection of the nail and nail bed and affects about 35 million people in the United States, Anacor said.

  • FDA approves Spectrum Pharma's blood cancer drug Thursday, 3 Jul 2014 | 11:19 AM ET

    July 3- Spectrum Pharmaceuticals Inc's drug for the treatment of an aggressive form of blood cancer was granted an accelerated approval by the U.S. Food and Drug Administration on Thursday. Beleodaq is the third drug to win approval for the condition since 2009, the other two being Spectrum's injection Folotyn and Celgene Corp's drug Istodax.

  • TEL AVIV, July 3- Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration, aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis.

  • July 2- St. Jude Medical Inc said the U.S. Food and Drug Administration notified the company that issues regarding its Sylmar, California- based manufacturing plant have been resolved. The FDA last year had warned St.

  • July 2- St. Jude Medical Inc said the U.S. Food and Drug Administration notified the company that issues regarding its Sylmar, California- based manufacturing plant have been resolved. The FDA last year had warned St. Jude of serious violations at the plant where the Durata and Riata leads for implantable defibrillators are made.

  • June 30- Allergan Inc said on Monday that the U.S. Food and Drug Administration would not approve its acute migraine aerosol treatment until certain concerns are addressed, but the agency approved a new use for its implantable eye drug, Ozurdex.

  • June 30- Allergan Inc said on Monday the U.S. Food and Drug Administration had raised issues about its application for a new acute migraine aerosol but had separately approved a treatment for diabetic macular edema.

  • June 30- Allergan Inc on Monday said the U.S. Food and Drug Administration had raised issues about its application for a new acute migraine treatment and that it was working with the agency to address them.

  • WASHINGTON, June 27- The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann. It acts more rapidly than injectable insulins such as Eli Lilly and Co's Humalog and Novo Nordisk's NovoLog.

  • WASHINGTON, June 27- The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann. It acts more rapidly than traditional injected insulin sold by Eli Lilly and Co and Denmark's Novo Nordisk.

  • Finding the cure for blindness     Friday, 27 Jun 2014 | 7:42 AM ET

    Gordon Gund, Gund Investment Corp. chairman & CEO, who lost his sight 40 years ago, discusses his goal to raise $100 million to fund research for a cure for blindness.

  • FDA ruling a win for paraplegic community     Friday, 27 Jun 2014 | 6:52 AM ET

    Larry Jasinski, ReWalk Robotics CEO, discusses how the FDA's decision will likely improve the lives of wheelchair bound people. This is such groundbreaking technology that the FDA put a new classification code for this product, explains Jasinski.

  • WASHINGTON/ MUMBAI, June 27- India's Ranbaxy Laboratories Ltd has received approval from the U.S. Food and Drug Administration to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.